Video

Dr. Gupta on safety and sequencing of antibody-drug conjugates in urothelial cancer

Video Player is loading.
Current Time 0:00
Duration 0:52
Loaded: 18.60%
Stream Type LIVE
Remaining Time 0:52
 
1x
    • Chapters
    • descriptions off, selected
    • captions off, selected
    • en (Main), selected

    Shilpa Gupta, MD, director of Genitourinary Oncology at Cleveland Clinic compares the safety profile of the antibody-drug conjugates (ADCs) sacituzumab govitecan (Trodelvy) and enfortumab vedotin (Padcev). Both ADCs are FDA-approved for the treatment of patients with locally advanced or metastatic urothelial cancer previously treated with chemotherapy and a PD-1/PD-L1 inhibitor.

    © 2025 MJH Life Sciences

    All rights reserved.